Perhaps my favorite tribute was this tweet , featuring a hilarious description of Steely Dan's very specific iconography and semiotics: "Honestly sad about Walter Becker and am also too irony poisoned to think of a more fitting tribute than this".
North Korea's weapons program has been progressing at a rapid pace under leader Kim Jong Un. In its report, KCNA (via Xinhua , China's official news agency) also said the North Korean leader "guided the work for nuclear weaponization on the spot", as part of "the final-stage research and development for perfecting the state nuclear force".
Now O'Neill needs to fire Ireland's burners ahead of the Serbia game on Tuesday that could make or break his hopes of qualifying for the World Cup in Russian Federation next summer. Rarely got forward until the final minutes. "There is a lot at stake, we are playing away from home and maybe we would have been happy with a point, but we didn't keep the ball well enough".
Cameroon (yellow) were in charge of the early exchanges. The Eagles nearly had a third before half time by Teikeu did well to clear Victor Moses cross after a counter-attack. Any hopes Cameroon had of clawing their way back into the contest were ended in the 55th minute when the impressive Moses - so often Nigeria's saviour during some of their biggest matches over the last four years - beat Ondoa after a counter attack.
In 2012, Penn and Novartis entered into a global collaboration to further research, develop and commercialize Kymriah and other CAR-T cell therapies for the treatment of cancers. Novartis, the company behind Kymriah, claims it takes around 22 days to produce an individual treatment for a patient. The hope is that one day doctors will be able to prescribe a cell therapy and use it that same day instead of waiting weeks to get it back.
Novartis , the Swiss pharmaceutical company who helped develop the treatment, announced they are "so proud to be part of this historic moment in cancer treatment". The trial was successful, with 83% of the 63 clinical patients treated for relapsed or refractory B-cell undergoing successful remission within three months of treatment.